The author wishes to disclose that in the last two years he has lectured and served on advisory board honoraria or engaged in clinical trial activities with Angelini, Lundbeck, Janssen, Otsuka, and Allergan.
The author apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
suicide, treatment outcome, relapse, adherence, prevention
Citation
Pompili M (2020) Corrigendum: Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics. Front. Psychiatry 11:101. doi: 10.3389/fpsyt.2020.00101
Received
05 February 2020
Accepted
06 February 2020
Published
27 February 2020
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2020
Updates
Copyright
© 2020 Pompili.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maurizio Pompili, maurizio.pompili@uniroma1.it
This article was submitted to Mood and Anxiety Disorders, a section of the journal Frontiers in Psychiatry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.